PL3178472T3 - Doustne preparaty metylonaltreksonu - Google Patents

Doustne preparaty metylonaltreksonu

Info

Publication number
PL3178472T3
PL3178472T3 PL17153285T PL17153285T PL3178472T3 PL 3178472 T3 PL3178472 T3 PL 3178472T3 PL 17153285 T PL17153285 T PL 17153285T PL 17153285 T PL17153285 T PL 17153285T PL 3178472 T3 PL3178472 T3 PL 3178472T3
Authority
PL
Poland
Prior art keywords
methylnaltrexone
oral formulations
formulations
oral
Prior art date
Application number
PL17153285T
Other languages
English (en)
Inventor
Syed M. Shah
Christopher Richard Diorio
Eric C. Ehrnsperger
Xu Meng
Kadum A. Shareffi
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3178472(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL3178472T3 publication Critical patent/PL3178472T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL17153285T 2010-03-11 2011-03-11 Doustne preparaty metylonaltreksonu PL3178472T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
EP17153285.6A EP3178472B1 (en) 2010-03-11 2011-03-11 Oral formulations of methylnaltrexone
EP11157837.3A EP2371357B1 (en) 2010-03-11 2011-03-11 Oral formulations and lipophilic salts of methylnaltrexone

Publications (1)

Publication Number Publication Date
PL3178472T3 true PL3178472T3 (pl) 2022-02-14

Family

ID=44148539

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11157837T PL2371357T3 (pl) 2010-03-11 2011-03-11 Doustne preparaty i lipofilowe sole metylonaltreksonu
PL17153285T PL3178472T3 (pl) 2010-03-11 2011-03-11 Doustne preparaty metylonaltreksonu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11157837T PL2371357T3 (pl) 2010-03-11 2011-03-11 Doustne preparaty i lipofilowe sole metylonaltreksonu

Country Status (32)

Country Link
US (8) US8524276B2 (pl)
EP (2) EP3178472B1 (pl)
JP (4) JP6143409B2 (pl)
KR (2) KR101982482B1 (pl)
CN (2) CN102918039B (pl)
AR (1) AR080491A1 (pl)
AU (1) AU2011224275B2 (pl)
BR (1) BR112012022873B1 (pl)
CA (1) CA2789798C (pl)
CL (1) CL2012002192A1 (pl)
CO (1) CO6630134A2 (pl)
CR (1) CR20120476A (pl)
EA (1) EA029096B1 (pl)
EC (1) ECSP12012208A (pl)
ES (1) ES2623926T3 (pl)
GE (1) GEP201606550B (pl)
GT (1) GT201200247A (pl)
HU (1) HUE033133T2 (pl)
IL (1) IL221452A (pl)
MA (1) MA34146B1 (pl)
MX (2) MX368805B (pl)
MY (1) MY160727A (pl)
NZ (3) NZ601595A (pl)
PE (1) PE20130063A1 (pl)
PH (1) PH12012501622A1 (pl)
PL (2) PL2371357T3 (pl)
SG (3) SG10201606618PA (pl)
TN (1) TN2012000392A1 (pl)
TW (2) TWI589293B (pl)
UA (2) UA123856C2 (pl)
WO (1) WO2011112816A1 (pl)
ZA (1) ZA201808498B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
EP2164960A2 (en) 2007-05-25 2010-03-24 North Carolina State University Viral nanoparticle cell-targeted delivery platform
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
AU2012359013A1 (en) * 2011-12-19 2014-06-26 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CN113747882A (zh) * 2019-05-07 2021-12-03 博士医疗爱尔兰有限公司 甲基纳曲酮的液体口服剂量制剂
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
CZ297951B6 (cs) 1997-02-14 2007-05-02 Gödecke Aktiengesellschaft Zpusob stabilizace naloxonu
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
EP2236161A1 (en) 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
MXPA04005210A (es) * 2001-11-29 2004-08-19 Schering Corp Procedimiento para la preparacion de composiciones que tienen una cantidad incrementada de sales farmaceuticamente activas de rotameros.
ATE510534T1 (de) 2002-03-14 2011-06-15 Euro Celtique Sa Naltrexonhydrochlorid-zusammensetzungen
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
AU2004229464A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
EP1701699B1 (en) 2003-12-19 2011-07-13 Schering Corporation Pharmaceutical compositions of an A2a receptor antagonist
WO2005065656A2 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
ES2392645T3 (es) 2004-09-30 2012-12-12 Becton,Dickinson And Company Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
CA2660100C (en) * 2006-08-16 2014-10-21 Alcon Inc. Temporal photo-bleaching of colored lens care solutions and use thereof
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CA2682129A1 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
SG183133A1 (en) 2012-09-27
MY160727A (en) 2017-03-15
PH12012501622A1 (en) 2012-11-05
MA34146B1 (fr) 2013-04-03
JP2016029054A (ja) 2016-03-03
TWI605814B (zh) 2017-11-21
SG10201501821RA (en) 2015-05-28
CN107308125A (zh) 2017-11-03
SG10201606618PA (en) 2016-09-29
JP2011190259A (ja) 2011-09-29
CO6630134A2 (es) 2013-03-01
US10507206B2 (en) 2019-12-17
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
US20190117645A1 (en) 2019-04-25
IL221452A (en) 2017-07-31
CR20120476A (es) 2012-11-30
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
JP6647368B2 (ja) 2020-02-14
MX349145B (es) 2017-07-14
EP2371357B1 (en) 2017-02-01
IL221452A0 (en) 2012-10-31
NZ601595A (en) 2015-01-30
US10376505B2 (en) 2019-08-13
US20200121673A1 (en) 2020-04-23
US8524276B2 (en) 2013-09-03
US20120070495A1 (en) 2012-03-22
US20130330407A1 (en) 2013-12-12
PE20130063A1 (es) 2013-02-11
EA201270741A1 (ru) 2013-02-28
CL2012002192A1 (es) 2012-09-28
JP2017206553A (ja) 2017-11-24
TN2012000392A1 (en) 2014-01-30
ES2623926T3 (es) 2017-07-12
HK1245673A1 (zh) 2018-08-31
KR20180118260A (ko) 2018-10-30
US20140249171A1 (en) 2014-09-04
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
JP6143409B2 (ja) 2017-06-07
US20160206612A1 (en) 2016-07-21
BR112012022873B1 (pt) 2021-09-14
CA2789798C (en) 2020-09-22
ECSP12012208A (es) 2015-03-31
US20190314365A1 (en) 2019-10-17
PL2371357T3 (pl) 2017-09-29
KR20130010900A (ko) 2013-01-29
UA111717C2 (uk) 2016-06-10
GEP201606550B (en) 2016-10-10
TW201141479A (en) 2011-12-01
AR080491A1 (es) 2012-04-11
HUE033133T2 (en) 2017-11-28
EA029096B1 (ru) 2018-02-28
GT201200247A (es) 2013-09-11
JP2019034958A (ja) 2019-03-07
AU2011224275A1 (en) 2012-08-23
KR101913102B1 (ko) 2018-10-31
EP3178472B1 (en) 2021-10-27
TW201622724A (zh) 2016-07-01
CN102918039A (zh) 2013-02-06
CN107308125B (zh) 2021-07-16
NZ702826A (en) 2016-08-26
US9314461B2 (en) 2016-04-19
UA123856C2 (uk) 2021-06-16
US20190117646A1 (en) 2019-04-25
BR112012022873A2 (pt) 2016-08-30
MX2012009125A (es) 2012-09-07
US10307417B2 (en) 2019-06-04
MX368805B (es) 2019-10-17
NZ703564A (en) 2016-08-26
EP2371357A1 (en) 2011-10-05
JP6429955B2 (ja) 2018-11-28
WO2011112816A1 (en) 2011-09-15
CN102918039B (zh) 2017-06-09
EP3178472A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
ZA201808498B (en) Oral formulations and lipophilic salts of methylnaltrexone
ZA201209156B (en) Therapeutic oral composition
IL221409A0 (en) Abuse-resistant formulations
PL2552382T3 (pl) Kompozycja do pielęgnacji jamy ustnej
GB201009368D0 (en) Dietary formulations
ZA201205804B (en) Oral care compositions
ZA201206068B (en) Oral care compositions
PL2555829T3 (pl) Kompozycje do pielęgnacji jamy ustnej
EP2552210A4 (en) FORMULAS FROM MAZINDOL
IL224192A (en) Compositions of Vitamin 14 – Epi Analogs d
ZA201304087B (en) Oral compositions
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations
GB201018760D0 (en) An oral dosage form
GB201000722D0 (en) Oral hygiene compositions
PL390434A1 (pl) Preparat leczniczy
GB201012589D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201018649D0 (en) Formulations